Valuation: Relay Therapeutics, Inc.

Market Cap 4.26B 3.7B 3.45B 3.17B 5.99B 405B 6.06B 40.65B 15.89B 202B 15.99B 15.64B 671B P/E 2026 *
-12.7x
P/E 2027 * -12.4x
Enterprise Value 3.97B 3.44B 3.21B 2.95B 5.58B 377B 5.64B 37.86B 14.8B 189B 14.9B 14.57B 625B EV / Sales 2026 *
336x
EV / Sales 2027 * 278x
Free-Float
93.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+6.07%
Current month+3.48%
1 month+3.10%
3 months+49.88%
6 months+139.08%
Current year+130.32%
1 week 18.1
Extreme 18.1
19.97
1 month 17.71
Extreme 17.71
20.79
Current year 7.01
Extreme 7.01
20.79
1 year 3.02
Extreme 3.025
20.79
3 years 1.78
Extreme 1.775
20.79
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap.
7/28/26 A Sell

Chief Financial Officer

-1,459 0.0007%
7/28/26 A Sell

Executive/Senior Manager

-748 0.0003%
7/28/26 A Sell

Chief Technology Officer

-2,237 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+6.07%+451.98%+87.90% 4.26B
+0.90%-2.33%+0.68%+14.52% 48B
+0.95%+7.29%+405.64%+554.91% 41.13B
+3.40%-4.90%+28.00%+7.36% 37.56B
+2.31%+0.98%+7.55%+76.21% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.64%-2.86% - - 16.12B
+1.41%-0.42%+33.51%+123.70% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.86%-8.06%-1.30%-34.88% 12.1B
Average +1.66%-1.25%+105.07%+99.24% 25.48B
Weighted average by Cap. +1.66%-1.16%+87.98%+125.99%

Financials

2026 *2027 *
Net sales 11.8M 10.25M 9.56M 8.78M 16.6M 1.12B 16.79M 113M 44.05M 561M 44.33M 43.36M 1.86B 14.5M 12.59M 11.74M 10.78M 20.4M 1.38B 20.62M 138M 54.11M 690M 54.46M 53.26M 2.28B
Net income -292M -254M -237M -217M -411M -27.8B -416M -2.79B -1.09B -13.9B -1.1B -1.07B -46.04B -312M -271M -253M -232M -439M -29.69B -444M -2.98B -1.16B -14.84B -1.17B -1.15B -49.17B
Net Debt -292M -254M -236M -217M -411M -27.78B -415M -2.79B -1.09B -13.89B -1.1B -1.07B -46.01B -221M -192M -179M -164M -311M -21.01B -314M -2.11B -824M -10.5B -829M -811M -34.8B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
05/08/26 $19.49 -0.26% 345,048
04/08/26 $19.54 +4.05% 2,054,518
03/08/26 $18.78 -0.27% 1,603,566
31/07/26 $18.83 -3.19% 1,785,640
30/07/26 $19.45 +5.88% 1,866,020
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
19.54USD
Average target price
26.08USD
Spread / Average Target
+33.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock